Physician profile
Wei Feng
NPI 1043277601
$9,347.04
in general payments reported to CMS, 2019-2025
48 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $780 · 2021: $984 · 2022: $644 · 2023: $1,609 · 2024: $1,258 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,759 · Honoraria: $300 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,759.00 |
| Honoraria | $300.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,197.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,166.98 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $954.08 | 2019-2025 | Evenity, Repatha |
| Mannkind Corporation | $695.47 | 2019-2024 | Afrezza |
| Lilly USA, LLC | $584.94 | 2020-2024 | Mounjaro |
| Dexcom, INC. | $574.41 | 2019-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $456.28 | 2019-2024 | |
| Radius Health, INC. | $448.15 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $306.81 | 2023-2024 | Korlym |
| Chiesi USA, INC. | $300.00 | 2025 | Mycapssa |
| Insulet Corporation | $299.40 | 2019-2025 | Omnipod, Omnipod |
| Sanofi-Aventis U.S. LLC | $257.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $235.33 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $190.95 | 2020-2024 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $151.41 | 2024-2025 | Crysvita |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Feng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.